Back to Search Start Over

Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance

Authors :
Nathalie Ganne-Carrié
Pierre Nahon
Cendrine Chaffaut
Gisèle N’Kontchou
Richard Layese
Etienne Audureau
Sylvie Chevret
Isabelle Archambeaud
Louis d’Alteroche
Frédéric Oberti
Dominique Roulot
Christophe Moreno
Alexandre Louvet
Thông Dao
Romain Moirand
Odile Goria
Eric Nguyen-Khac
Nicolas Carbonell
Jean-Charles Duclos-Vallée
Stanislas Pol
Victor de Ledinghen
Violaine Ozenne
Jean Henrion
Jean-Marie Péron
Albert Tran
Gabriel Perlemuter
Xavier Amiot
Jean-Pierre Zarski
Tarik Asselah
Dominique Guyader
Hélène Fontaine
Georges-Philippe Pageaux
Victor De Lédinghen
Denis Ouzan
Fabien Zoulim
Jean-Pierre Bronowicki
Thomas Decaens
Ghassan Riachi
Paul Calès
Laurent Alric
Marc Bourlière
Philippe Mathurin
Sebastien Dharancy
Jean-Frédéric Blanc
Armand Abergel
Olivier Chazouillères
Ariane Mallat
Jean-Didier Grangé
Pierre Attali
Claire Wartelle
Dominique Thabut
Christophe Pilette
Christine Silvain
Christos Christidis
Brigitte Bernard-Chabert
Sophie Hillaire
Vincent Di Martino
Hôpital Avicenne [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Université Sorbonne Paris Nord
Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138))
École pratique des hautes études (EPHE)
Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)
Service de biostatistique et information médicale de l’hôpital Saint Louis (Equipe ECSTRA) (SBIM)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut national du cancer [Boulogne] (INCA)-Hopital Saint-Louis [AP-HP] (AP-HP)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité)
Hôpital Henri Mondor
Clinical Epidemiology and Ageing : Geriatrie Soins Primaires et Santé Publique (CEpiA)
Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
ANRS CO12 CirVir group: Pierre Nahon1, Tarik Asselah2, Dominique Guyader3, Stanislas Pol4, Hélène Fontaine4, Georges-Philippe Pageaux5, Victor De Lédinghen6, Denis Ouzan7, Fabien Zoulim8, Dominique Roulot9, Albert Tran10, Jean-Pierre Bronowicki11, Thomas Decaens12, Ghassan Riachi13, Paul Calès14, Jean-Marie Péron15, Laurent Alric16, Marc Bourlière17, Philippe Mathurin18, Sebastien Dharancy18, Jean-Frédéric Blanc19, Armand Abergel20, Olivier Chazouillères21, Ariane Mallat22, Jean-Didier Grangé23, Pierre Attali24, Louis d’Alteroche25, Claire Wartelle26, Thông Dao27, Dominique Thabut28, Christophe Pilette29, Christine Silvain30, Christos Christidis31, Eric Nguyen-Khac32, Brigitte Bernard-Chabert 33, Sophie Hillaire34, Vincent Di Martino35. 1AP-HP, Hôpital Avicenne, Service d’Hépatologie, Bobigny, Université Sorbonne Paris Nord, Bobigny et INSERM U1138, Université de Paris
2AP-HP, Hôpital Beaujon, Service d’Hépatologie, and University Paris Diderot, Sorbonne Paris Cité, CRI, UMR 1149
3CHU Pontchaillou, Service d’Hépatologie, Rennes
4AP-HP, Hôpital Cochin, Département d’Hépatologie et INSERM UMS20 et U1223, Institut Pasteur, Université Paris Descartes, Paris
5Hôpital Saint Eloi, Service d’Hépatologie, Montpellier
6Hôpital Haut-Lévêque, Service d’Hépatologie, Bordeaux
7Institut Arnaud Tzanck, Service d’Hépatologie, St Laurent du Var
8Hôpital Hôtel Dieu, Service d’Hépatologie, Lyon
9AP-HP, Hôpital Avicenne, Service de Medeine Interne, Bobigny
10CHU de Nice, Service d’Hépatologie, et INSERM U1065, Université de Nice-Sophia-Antipolis, Nice
11Hôpital Brabois, Service d’Hépatologie, Vandoeuvre-les-Nancy
12Hôpital Michallon, Service d’Hépatologie, Grenoble
13Hôpital Charles-Nicolle, Service d’Hépatologie, Rouen
14CHU d’Angers, Service d’Hépatologie, Angers
15Hôpital Purpan, Service d’Hépatologie, Toulouse
16CHU Toulouse, Service de Médecine Interne-Pôle Digestif UMR 152, Toulouse
17Hôpital Saint Joseph, Service d’Hépatologie, Marseille
18Hôpital Claude Huriez, Service d’Hépatologie, Lille
19Hôpital St André, Service d’Hépatologie, Bordeaux
20Hôpital Hôtel Dieu, Service d’Hépatologie, Clermont-Ferrand
21AP-HP, Hôpital Saint-Antoine, Service d’Hépatologie, Paris
22AP-HP, Hôpital Henri Mondor, Service d’Hépatologie, Créteil
23AP-HP, Hôpital Tenon, Service d’Hépatologie, Paris
24AP-HP, Hôpital Paul Brousse, Service d’Hépatologie, Villejuif
25Hôpital Trousseau, Unité d’Hépatologie, CHRU de Tours
26Hôpital d’Aix-En-Provence, Service d’Hépatologie, Aix-En-Provence
27Hôpital de la Côte de Nacre, Service d’Hépatologie, Caen
28AP-HP, Groupe Hospitalier de La Pitié-Salpêtrière, Service d’Hépatologie, Paris
29CHU Le Mans, Service d’Hépatologie, Le Mans
30CHU de Poitiers, Service d’Hépatologie, Poitiers
31Institut Mutualiste Montsouris, Service d’Hépatologie, Paris
32Hôpital Amiens Nord, Service d’Hépatologie, Amiens
33Hôpital Robert Debré, Service d’Hépatologie, Reims
34Hôpital Foch, Service d’Hépatologie, Suresnes
35Hôpital Jean Minjoz, Service d’Hépatologie, Besançon. France.
CIRRAL group: Nathalie Ganne-Carrié1, Cendrine Chaffaut2, Isabelle Archambeaud3, Louis d’Alteroche4, Frédéric Oberti5, Dominique Roulot6, Christophe Moreno7, Alexandre Louvet8, Thông Dao9, Romain Moirand10, Odile Goria11, Eric Nguyen-Khac12, Nicolas Carbonell13, Jean-Charles Duclos-Vallée14, Stanislas Pol15,16, Victor de Ledinghen17, Violaine Ozenne18, Jean Henrion19, Jean-Marie Péron20, Albert Tran21,22, Gabriel Perlemuter23, Xavier Amiot24, Jean-Pierre Zarski25, Sylvie Chevret2. 1AP-HP, Hôpital Avicenne, Service d’Hépatologie, Bobigny, Université Sorbonne Paris Nord, Bobigny et INSERM U1138, Université de Paris
2SBIM, APHP, Hôpital Saint-Louis, Paris, Inserm, UMR-1153, ECSTRA Team, Paris, France
3Liver, CHU, Nantes, France
4Liver Unit, University Hospital, Tours, France
5Liver Unit, University Hospital, Angers, France
6AP-HP, Hôpital Avicenne, Service de Médecine Interne, Bobigny, Université Sorbonne Paris Nord, Bobigny
7Liver unit, CUB Hôpital Erasme, Université Libre de Bruxelles, Belgium, 8Liver Unit, University Hospital, Lille, France, 9Liver Unit, University Hospital, Caen, France
10Liver Unit, University Hospital, Rennes, France
11Liver Unit, University Hospital, Rouen, France
12Liver Unit, University Hospital, Amiens, France
13 Liver Unit, APHP, CHU Saint-Antoine, Paris, France
14Liver Unit, APHP, CHU Paul Brousse, Villejuif, France
15Université Paris Descartes
APHP, Liver Unit, Hôpital Cochin
16INSERM U1223, Institut Pasteur, Paris, France
17Hepatology Unit, University Hospital, CHU Bordeaux, France
18Liver Unit, APHP, CHU Lariboisière, Paris, France
19Liver Unit, University Hospital, Haine Saint-Paul, Belgium, 20Liver Unit, Universitary Hospital Purpan, University Paul Sabatier III, Toulouse
21Institut National de la Santé et de la Recherche Médicale (INSERM), U1065, Team 8, 'Hepatic Complications in Obesity', Nice, F-06204, Cedex 3, France
22University Hospital of Nice, Digestive Centre, Nice, F-06202, Cedex 3, France
23Liver Unit, University Hospital, Béclère, APHP, Clamart, France
24Liver Unit, APHP, CHU Tenon, Paris, France
25Clinique d’hépato-gastroentérologie pôle Digidune CHU de Grenoble, France
Source :
JHEP Reports, JHEP Reports Innovation in Hepatology, JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (3), pp.100285. ⟨10.1016/j.jhepr.2021.100285⟩, JHEP Reports, Vol 3, Iss 3, Pp 100285-(2021)
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

Background & Aims In this study we aimed to analyse the impact of the aetiology of cirrhosis on the incidence, characteristics and prognosis of hepatocellular carcinoma (HCC) diagnosed during a surveillance program. Methods Individual data from a randomized trial and 2 prospective cohorts of patients with compensated histologically proven cirrhosis recruited between 2000 and 2016 were pooled. The influence of cirrhosis aetiology on survival after HCC detection was assessed using multivariable regression models. Results Among 3,533 patients (1,926 virus [VIR], 1,167 alcohol [ALC], 440 combined [MIX]), 431 were diagnosed with HCC after a median follow-up of 57.1 months. The 5-year HCC incidence was lowest in ALC (VIR 12.6%, ALC 9.1%, MIX 14.3%, p = 0.04). At the time of diagnosis, tumour burden and Child-Pugh score were comparable across aetiology groups, but early BCLC stages (0/A) were significantly less frequent in ALC (VIR 80%, ALC 37%, MIX 72%) as a result of worse ECOG performance status. However, similar access to first-line curative HCC treatment was reported across aetiology groups (p = 0.68). Median survival after HCC diagnosis was significantly reduced in ALC (VIR 39, ALC 21, MIX 34 months, p = 0.02). However, when adjusting for tumour size, ECOG and Child-Pugh score, the aetiology of the underlying cirrhosis no longer had a significant impact. Conclusion Compared to patients with virus-related cirrhosis, patients with alcohol-related compensated cirrhosis enrolled in a surveillance program have: i) the lowest 5-year HCC incidence; ii) worse overall prognosis, mostly driven by a poor general condition, despite similar access to first-line curative treatment. Lay summary It has been suggested that early detection of hepatocellular carcinoma (HCC) may be futile in patients with alcohol-related cirrhosis. By comparing outcomes in more than 3,000 patients with compensated cirrhosis included in surveillance programs, this study suggests that HCC surveillance enables early diagnosis in most patients with alcohol-related cirrhosis despite a higher competing risk of death in these patients. We also report similar access to first-line curative HCC treatment in these patients compared to those with viral cirrhosis, despite higher rates of comorbidities and impaired liver function. Following HCC detection, the later parameters were major drivers of death irrespective of the cause of cirrhosis. Registration CHC2000 (NCT00190385) and CIRRAL (NCT01213927) cohorts were registered at ClinicalTrials.gov and the full protocols are available at the following links (https://clinicaltrials.gov/ct2/show/NCT00190385) and https://clinicaltrials.gov/ct2/show/NCT01213927, respectively). The full CirVir protocol is available via the ANRS Web site (http://anrs.fr).<br />Graphical abstract<br />Highlights • Alcohol-related cirrhosis linked to the lowest incidence of HCC, the lowest overall survival and the highest incidence of decompensation. • Alcohol-related cirrhosis linked to fewer cases of early stage HCC, although tumour burden and Child-Pugh score were comparable across groups. • Patients with alcohol-related cirrhosis had worse survival after HCC diagnosis than those with virus-related cirrhosis. • The aetiology of cirrhosis had no impact on survival after HCC diagnosis following adjustment for other potential prognostic factors.

Details

Language :
English
ISSN :
25895559
Volume :
3
Issue :
3
Database :
OpenAIRE
Journal :
JHEP Reports
Accession number :
edsair.doi.dedup.....eb6360b4ce02a4a446734be7cd50e485
Full Text :
https://doi.org/10.1016/j.jhepr.2021.100285⟩